- Sat Jun 20, 2020 12:57 pm
#125900
The National Institutes of Health (NIH) has halted its clinical trial of hydroxychloroquine, saying that while there are no ill side effects, the anti-malaria drug provides no benefit to COVID-19 patients.
"A data and safety monitoring board (DSMB) met late Friday and determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19," the NIH said in a statement.
It added, "The data from this study indicate that this drug provided no additional benefit compared to placebo control for the treatment of COVID-19 in hospitalized patients."
"A data and safety monitoring board (DSMB) met late Friday and determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19," the NIH said in a statement.
It added, "The data from this study indicate that this drug provided no additional benefit compared to placebo control for the treatment of COVID-19 in hospitalized patients."